Latest news with #Tilray
The Market Online
4 days ago
- Business
- The Market Online
Diversify away from cannabis retail with this technology stock
While overproduction, inflation and the glacial pace of legalization have humbled the top Canadian cannabis stocks, such as Tilray (TSX:TLRY) and Canopy Growth (TSX:WEED), from large-cap glory to small-cap question marks, there are certain companies that have managed to generate long-term shareholder value, despite the volatility of a nascent industry, giving investors every reason to expect continued growth into the future. A stock well worth your attention under this lens is Cannabix Technologies (CSE:BLO), market capitalization C$69.09 million, a technology developer specializing in cannabis and alcohol breathalyzers for workplaces, law enforcement, laboratories and other critical settings. The company has been on a role over the past 12 months, achieving positive third-party testing for its alcohol and cannabis-detection technologies, reducing net losses by over 75 per cent from C$2.08 million to C$450,000, in addition to securing a handful of deals that set operations up for revenue generation. These include: Cannabix's latest milestone, a contract manufacturing deal with Price Industries in Winnipeg, Manitoba, announced earlier this week, continues to demonstrate the company's ability to attract well-established partners and pave out its long-term growth runway. The company's diligent product development and consistency at closing deals have earned investors a 76.47-per-cent return year-to-date, an over 250-per-cent return from the five-year low in 2023, and an over 350 per cent return since adopting the Cannabix name in 2014, all of which has come before reporting any revenue on the balance sheet. Once initial orders roll in and Cannabix's top line starts to put up positive numbers, look for the broader market to pile in and reward the patience of long-term investors. While there's no specific timeline for this, the company is well-capitalized to continue building strategic relationships and go-to-market momentum with over C$2.8 million in cash as of January 2025. Join the discussion: Find out what everybody's saying about this alcohol and cannabis breathalyzer technology stock on the Cannabix Technologies Inc. Bullboard and check out the rest of Stockhouse's stock forums and message boards. The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
Yahoo
4 days ago
- Business
- Yahoo
Beverages, Alcohol, and Tobacco Stocks Q1 In Review: Tilray (NASDAQ:TLRY) Vs Peers
As the Q1 earnings season comes to a close, it's time to take stock of this quarter's best and worst performers in the beverages, alcohol, and tobacco industry, including Tilray (NASDAQ:TLRY) and its peers. These companies' performance is influenced by brand strength, marketing strategies, and shifts in consumer preferences. Changing consumption patterns are particularly relevant and can be seen in the rise of cannabis, craft beer, and vaping or the steady decline of soda and cigarettes. Companies that spend on innovation to meet consumers where they are with regards to trends can reap huge demand benefits while those who ignore trends can see stagnant volumes. Finally, with the advent of the social media, the cost of starting a brand from scratch is much lower, meaning that new entrants can chip away at the market shares of established players. The 15 beverages, alcohol, and tobacco stocks we track reported a mixed Q1. As a group, revenues missed analysts' consensus estimates by 0.5%. In light of this news, share prices of the companies have held steady as they are up 2.2% on average since the latest earnings results. Founded in 2013, Tilray Brands (NASDAQ:TLRY) engages in cannabis research, cultivation, and distribution, offering a range of medical and recreational cannabis products, hemp-based foods, and alcoholic beverages. Tilray reported revenues of $185.8 million, down 1.4% year on year. This print fell short of analysts' expectations by 10.1%. Overall, it was a slower quarter for the company with a significant miss of analysts' EBITDA and gross margin estimates. Irwin D. Simon, Chairman and Chief Executive Officer of Tilray Brands, stated, "Tilray Brands is shaping the future of consumer markets with a robust global infrastructure spanning the beverage, cannabis, and wellness industries. We are meeting the needs of today's consumers while preparing for the demands of tomorrow. In the third quarter, we prioritized sales quality and revenue, protected margins, reduced debt, and improved our capital structure. With a strong balance sheet and a clear vision for the future, Tilray is well positioned to capitalize on emerging opportunities and ensure long-term success.' Tilray delivered the weakest performance against analyst estimates and weakest full-year guidance update of the whole group. The stock is down 21.3% since reporting and currently trades at $0.46. Read our full report on Tilray here, it's free. With a primary focus on soda but also a presence in energy drinks and teas, Zevia (NYSE:ZVIA) is a better-for-you beverage company. Zevia reported revenues of $38.02 million, down 2% year on year, outperforming analysts' expectations by 1.7%. The business had a very strong quarter with a solid beat of analysts' EPS estimates and an impressive beat of analysts' EBITDA estimates. The market seems happy with the results as the stock is up 35.3% since reporting. It currently trades at $2.76. Is now the time to buy Zevia? Access our full analysis of the earnings results here, it's free. Sporting an impressive roster of iconic beer brands, Molson Coors (NYSE:TAP) is a global brewing giant with a rich history dating back more than two centuries. Molson Coors reported revenues of $2.30 billion, down 11.3% year on year, falling short of analysts' expectations by 5.1%. It was a disappointing quarter as it posted a significant miss of analysts' adjusted operating income estimates. As expected, the stock is down 6.1% since the results and currently trades at $53.34. Read our full analysis of Molson Coors's results here. A pioneer and behemoth in carbonated soft drinks, Coca-Cola (NYSE:KO) is a storied beverage company best known for its flagship soda. Coca-Cola reported revenues of $11.22 billion, flat year on year. This result topped analysts' expectations by 0.6%. Aside from that, it was a satisfactory quarter as it also recorded a decent beat of analysts' organic revenue estimates but EBITDA in line with analysts' estimates. The stock is flat since reporting and currently trades at $71.15. Read our full, actionable report on Coca-Cola here, it's free. Known for its flavorful beverages challenging the status quo, Boston Beer (NYSE:SAM) is a pioneer in craft brewing and a symbol of American innovation in the alcoholic beverage industry. Boston Beer reported revenues of $453.9 million, up 6.5% year on year. This number surpassed analysts' expectations by 4.1%. It was a very strong quarter as it also logged an impressive beat of analysts' EPS estimates and a solid beat of analysts' EBITDA estimates. Boston Beer scored the biggest analyst estimates beat among its peers. The stock is down 5.6% since reporting and currently trades at $228.55. Read our full, actionable report on Boston Beer here, it's free. Thanks to the Fed's rate hikes in 2022 and 2023, inflation has been on a steady path downward, easing back toward that 2% sweet spot. Fortunately (miraculously to some), all this tightening didn't send the economy tumbling into a recession, so here we are, cautiously celebrating a soft landing. The cherry on top? Recent rate cuts (half a point in September 2024, a quarter in November) have propped up markets, especially after Trump's November win lit a fire under major indices and sent them to all-time highs. However, there's still plenty to ponder — tariffs, corporate tax cuts, and what 2025 might hold for the economy. Want to invest in winners with rock-solid fundamentals? Check out our Strong Momentum Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. Join Paid Stock Investor Research Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Business
- Yahoo
Tilray Brands to Present at TD Cowen's 9th Annual Future of the Consumer Conference
NEW YORK and LEAMINGTON, Ontario, May 29, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ('Tilray') (NASDAQ: TLRY and TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, today announced that Irwin D. Simon, Chairman and Chief Executive Officer, and Carl Merton, Chief Financial Officer, will participate in a fireside chat and host one-on-one meetings at the TD Cowen 9th Annual Future of the Consumer Conference on June 3, 2025, in New York, NY. The fireside chat is scheduled for 11:00 a.m. ET and a webcast will be available on Events & Presentations section of Tilray's Investor Relations website. To schedule a one-on-one meeting, please reach out to your TD Cowen representative. About Tilray Brands Tilray Brands, Inc. ('Tilray') (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray's mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray's unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages. For more information on how we are elevating lives through moments of connection, visit and follow @Tilray on all social platforms. Contacts: Investor Relationsinvestors@ Medianews@ in to access your portfolio
USA Today
23-05-2025
- Sport
- USA Today
Breckenridge's Spring Forward IPA is a throwback. It's a toss up whether that's good
Breckenridge's Spring Forward IPA is a throwback. It's a toss up whether that's good Welcome back to FTW's Beverage of the Week series. Here, we mostly chronicle and review beers, but happily expand that scope to any beverage that pairs well with sports. Yes, even cookie dough whiskey. Breckenridge feels like it's always been there. Maybe not with the cache of a Sam Adams or a Sierra Nevada, but lurking on the shelves of your local bottle shop since you hit drinking age. The brewer has, in fact, only been around since 1990. Which, sources tell me is 35 years ago and... good god. My own existential crisis aside, it seemed to embody the rising tide of craft brewing in that era. It made interesting beers outside the lagers that dominated America's macrobreweries. It had funky packaging and art. It came from the exotic land of Colorado, home of John Elway and neon ski pants. What wasn't to like? Despite all these positives, it never seemed to break through the way its peers did. Even now, as part of a national conglomerate (Tilray), Breckenridge feels more like the Errict Rhett in a league of Emmitt Smiths. Now that I've appropriately remembered a guy -- not an insult! Rhett was good! For the time! -- let's take a look at Breckenridge's new spring seasonal. Spring Forward Grapefruit IPA: C+ It pours with a little less carbonation than expected, but still leaves a quarter inch head that lingers well after the bottle has emptied. The smell off the top is split between resin-y hops and grapefruit. Together it's a little rough, but also appealing in a "oh, so this could be interesting" kind of way. The first sip is more bitter than expected for a spring beer. The hops are tart but not especially juicy or danky. That puts a lot of the lift onto the grapefruit, which gets it about halfway up before running out of gas. The citrus lingers in the aftertaste and does mellow out that bitter hop taste, but the overall impression feels like a throwback to the early days of IPAs. Except, you know, with fruit. It's a little underwhelming and surprisingly... divisive? for a national craft brewer like Breckenridge. Which, honestly, makes me respect the effort a little more. There's a certain crispness that I appreciate. But the IPA of it all is a little simple and single note. You can do better. Would I drink it instead of a Hamm's? This a pass/fail mechanism where I compare whatever I'm drinking to my baseline cheap beer. That's the standby from the land of sky-blue waters, Hamm's. So the question to answer is: on a typical day, would I drink Breckenridge's Spring Forward IPA over a cold can of Hamm's? It's a totally fine pale ale. I'll stick with the Hamm's, though.
Yahoo
17-05-2025
- Business
- Yahoo
Tilray Brands (NasdaqGS:TLRY) Plans Reverse Stock Split
Tilray Brands recently announced plans for a reverse stock split to align its share structure with similar-sized companies and ensure compliance with Nasdaq's listing requirements. Simultaneously, the launch of their new beverage line, Cruisies, appears to have generated positive market reception. These developments may have supported the company's share price rise of 16% over the past week, outpacing the broader market's 5% increase. The company's focus on streamlining operations and expanding its product offerings potentially contributed added confidence among investors, enhancing overall shareholder returns during this period. Tilray Brands has 3 possible red flags we think you should know about. Uncover the next big thing with financially sound penny stocks that balance risk and reward. The announcement of a reverse stock split and new product line, Cruisies, may provide Tilray Brands with some near-term share price support. However, examining the longer-term performance reveals a different story, with the company experiencing a 75% total return decline over the past year, indicating significant challenges remain. Compared to the broader market's positive returns and the US Pharmaceuticals industry's 9.9% decline last year, Tilray's performance highlights its relative struggles amidst sector trends. The company's ongoing initiatives, like SKU rationalization and international expansions, could influence revenue growth forecasts, which are projected to rise at a rate slower than the market. Despite this, Tilray's negative earnings underscore the difficulty in adjusting to competitive pressures and macroeconomic conditions, with no forecasted profitability in the near term. Given the current share price of US$0.46 and a consensus price target of US$1.29, there remains a substantial gap, reflecting the market's skepticism about Tilray's ability to meet these projections in the prevailing landscape. The stock's recent price adjustment may not yet fully align with analyst expectations, indicating persistent uncertainties. Our valuation report here indicates Tilray Brands may be undervalued. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:TLRY. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error while retrieving data Sign in to access your portfolio Error while retrieving data
